In line with updated guidance from the GPhC and the CQC, we will only accept prescriptions for weight loss medications from prescribers who are registered with the CQC (Pharmacists are exempt from this guidance)
* To prescribe Wegovy, you must provide a valid CQC provider registration number, this has to be provided to us by the prescriber.
* Prescriptions for weight loss medication will not be dispensed unless a verified CQC number is held on the prescriber's account account.
* The prescriber also is required to input the BMI of the patient in the prescrption notes, if this is not present it might delay your order being shipped, as we contact the prescriber for the BMI.
Wegovy is a prescription only medicine indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of ≥ 30 kg/m2 (obesity), or ≥ 27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus). This item requires a prescription from a registered UK prescriber before it can be dispatched. Prescriptions must state the patient’s BMI and at least one underlying comorbidity as appropriate in the instructions column.
Wegovy (Semaglutide) FlexTouch solution for injection in pre-filled pen
Wegovy 1.0mg is a prescription only medicine indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of
≥ 30 kg/m2 (obesity), or
≥ 27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).
Mechanism of action:
Semaglutide is a GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1.
GLP-1 is a physiological regulator of appetite and calorie intake, and the GLP-1 receptor is present in several areas of the brain involved in appetite regulation.
Semaglutide has direct effects on areas in the brain involved in homeostatic regulation of food intake in the hypothalamus and the brainstem, and direct and indirect effects on areas involved in hedonic regulation of food intake, including the septum, thalamus and amygdala.
Contraindications:
Hypersensitivity to the active substance or to any of the excipients.
Store in a refrigerator at 2–8°C
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
This medicinal product is subject to additional monitoring. Healthcare professionals are asked to report any suspected adverse reactions using the Yellow Card Scheme: www.mhra.gov.uk/yellowcard
Wegovy comes with 4 Novofine needles as supplied by the manufacturer
EMC: https://www.medicines.org.uk/emc/product/13801
Patient Information Leaflet: https://www.medicines.org.uk/emc/files/pil.13799.pdf
